How is place of death from cancer changing and what affects it? Analysis of cancer registration and service data

E Davies*, KM Linklater1, RH Jack1, L Clark1 and H Møller1

King's College London, School of Medicine at Guy's, King's and St Thomas' Hospitals, Thames Cancer Registry, Capital House, 42 Weston Street, London SEI 3QD, UK

We aimed to compare trends in place of cancer death with the growth of palliative care and nursing home services, and investigate demographic, disease-related and area influences on individual place of death, using registration data for 216404 patients with breast, lung, colorectal and prostate cancer and aggregate data on services in South East England. Between 1985 and 1994 there was a trend away from hospital death (67-44%), to home (17-30%) and hospice death (8-20%). After 1995, this partly reversed. By 2002, hospital death rose to 47%, home death dropped to 23%, hospice death remained stable and nursing home death rose from 3 to 8%. Numbers of palliative care services increased, but trends for hospice and nursing home deaths most clearly followed the beds available. Cancer diagnosis and treatment influenced individual place of death, but between 1998 and 2002, age and area of residence were associated with most variation. Older patients and those living in more deprived areas died more often in hospitals and less often at home. Despite more palliative care services the proportion of people dying at home has not increased. Variation by age, deprivation and area of residence is unlikely to reflect patient preference. More active surveillance and planning must support policies for choice in end of life care.

British Journal of Cancer (2006) 95, 593-600. doi:10.1038/sj.bjc.6603305 www.bjcancer.com Published online 15 August 2006 © 2006 Cancer Research UK

Keywords: palliative care; place of death; cancer registration; health services researches

Most people say they would prefer to die at home, but in reality most patients in the UK spend their final days in hospital (WHO, 2004a). Over the last 30 years, hospices, palliative care teams and units have developed with the aim of improving care towards the end of life, and allowing people to die where they wish, if this is possible. Services have initially focused on patients with cancer, primarily because of the relative ease of predicting the course of this disease, and a national policy for supportive and palliative cancer care is now in place (House of Commons Health Committee, 2004; NICE, 2004a, b). There is, therefore, increasing interest in Europe about whether data on place of death can be used as an interim measure of the success of services provided (WHO, 2004a). Figures for England and Wales revealed a trend away from death in hospital or nursing homes to hospices between 1985 and 1994, but very little change in home deaths, which remained around 26%. However, this proportion varied between regions and was lowest in South East England across all age and cancer types (Higginson et al, 1998). For common cancers, individual, disease-related and area of residence factors were consistently associated with, but not strongly predictive of place of death. Men, patients aged under 74 years, those with lung or colorectal cancer or living in more affluent areas were more likely to die at home than women, patients aged over 75 years, those with breast cancer or those living in less affluent areas (Higginson et al, 1998, 1999).

The Thames Cancer Registry covers a population of 14 million people in South East England, an area with one of the highest concentrations of hospice and palliative care services in the UK (Hospice Information, 2006). We used Registry data to describe trends in place of death for common cancers and compared these to the growth of palliative care services and nursing homes between 1985 and 2002. We then investigated the relationship between demographic, disease-related factors and individual place of death throughout the period, and the additional influence of area of residence between 1998 and 2002.

METHODS

In the UK cancer registries record the occurrence of cancer in their residential populations as well as treatments given in the first 6 months after diagnosis. Information about death is provided by the National Health Service Central Register through the Office for National Statistics. Death certificates routinely record place of death and assign cancer as a main or contributing cause of death in part I of the certificate.

We extracted data on 216 404 residents in South East England who had been diagnosed with breast, lung, colorectal and prostate cancer between 1985 and 2002, and who died from their disease between 1985 and 2002. Cases where the only registration information was from the death certificate were not included. From death certificates, we classified death as occurring in NHS acute hospitals, hospices, long stay hospitals or nursing homes, private hospitals, at home or as unknown. We could identify nursing homes by their address, but death certificates do not

^{*}Correspondence: Dr E Davies E-mail: Elizabeth.Davies@kcl.ac.uk Received 30 May 2006; accepted 7 July 2006; published online 15 August



distinguish deaths in hospital palliative care units from those in other wards.

We extracted data on hospice and palliative care services from Hospice Information directories for 1985 - 2002 (Hospice Information, 2006) and calculated the number of hospice beds, home care teams, day care services, hospital palliative care or support teams and hospital support nurses in our area. We summed home care services regardless of their funding (independent, NHS and Macmillan Cancer Relief) or base (hospices, NHS hospital or community), although there was insufficient detail about Marie Curie home services to include these. We could not deduce team size or caseload. We also obtained aggregate data on numbers of beds in registered nursing homes from the Department of Health where this was available for 1991-2001. We first plotted the proportion of deaths occurring in each of home, hospital, hospice and nursing home against the growth of different services over time. Data on acute and general hospital beds in our area were available only between 1996 and 2002 and were not plotted.

We then took death in hospice, nursing home, NHS acute hospital and at home as our four dependent variables and fitted logistic regression models to identify individual demographic, disease-related and area of residence factors predicting in turn each of these outcomes versus the others. Our first analysis for the entire period 1985-2002 included sex, age at diagnosis, whether the diagnosis was based on clinical or microscopic evidence, primary site of cancer and treatment with surgery, radiotherapy, chemotherapy or hormone therapy. We also adjusted for year of death and years since diagnosis to examine trends over time. We grouped age into four bands: <65 years, 65-74 years, 75-84 years and 85 years plus. Our second analysis explored the additional influence of area of residence for the years 1998 - 2002. For this, we assigned each individual to an electoral ward and a cancer network using their postcode of residence. We calculated the deprivation score for each ward using the income domain of the Indices of Multiple Deprivation (IMD) 2000 for England (Department of Environment, 2000) and assigned individuals to a quintile of deprivation ranging from most (1) to least affluent (5) wards.

We present the results of logistic regression analyses as proportions of deaths occurring in each place for each factor. Proportions are easier to interpret than odds ratios, and were derived from a back calculation from the odds ratios obtained from the logistic regression analyses. We present unadjusted and adjusted proportions to show the effect of controlling for all other factors. Our large sample size means that many small differences reach statistical significance. We draw attention only to those factors producing at least five percentage points difference – a difference which we believe a clinical service might be interested to explore further.

RESULTS

The average age of death for patients in this cohort increased from 71.3 years in 1985 to 72.7 in 2002. The proportion dying at age of 85 years and over increased from 8 to 12% while the proportion dying between the age of 65 and 74 years dropped from 34 to 28%.

How has place of death changed?

Figure 1 suggests that the period 1985 – 2002 is best considered in two phases – before and after 1994. In the first phase, hospital deaths declined from 67 to 44% – a trend that appeared to be mirrored by a combined increase in home death from 17 to 30% and in hospice death from 8 to 20%. In the second phase, however, the movement away from hospital death appeared to partly reverse. Between 1995 and 2002 hospital death rose to 47%, nursing home death to 8%, hospice death remained stable and home deaths dropped to 23%. In 2002 – the last year of the study –




Figure I Trends for place of death for patients with breast, colorectal, lung and prostate cancer in South East England 1985–2002. *Note*: Figure excludes the proportion dying in private hospitals and patients where place of death was not known.

home death and nursing home death home appear to have increased slightly and hospital death to have decreased. During 1992 and 1995 there were changes in processing and receipt of our registry data which may be responsible for the 'mirroring' of trends in hospital and home deaths during this period. This artefact overlies but does not explain the reversal of overall trends which is also seen in national data for this period.

Figure 2 shows that during the first phase, while home and hospice death increased, the provision of home care services and hospice beds also increased. From 1995 onwards while nursing home death and hospital death increased, nursing home beds and, to a lesser degree, the sum of hospital palliative care services (teams and nurses) also increased. For nursing home deaths, unlike hospice deaths, there is a lag of several years between the rise of available beds in these services and deaths within them. The decline in home death occurring after 1995 did not appear to follow a substantial drop in the provision of palliative home care or day care services, which both remained stable, although during this period the availability of nursing home beds was increasing.

Which individual and disease-related factors affect place of death?

Table 1 shows unadjusted and adjusted proportions of deaths in each place for individual demographic and disease-related factor over the entire study period. Hospital death was more likely for patients aged over 75, those with lung or breast cancer, a clinical rather than microscopic diagnosis, and those not receiving radiotherapy. Home death was more likely for those with colorectal cancer and those aged less than 75 years. Hospice death was also more likely for colorectal cancer and for those aged less than 75 years. Nursing home death increased with older age (4% for those aged 65–74 years and 12% of those aged over 85 years).

Did place of residence affect place of death between 1998 and 2002?

Our analysis for the most recent years included area of residence as assessed by cancer network of residence and deprivation of ward of residence (Table 2). The results for demographic and disease-related factors were broadly similar to those in Table 1, although nursing home deaths become more likely for those with breast and prostate cancer. However, much more striking was the variation by




Figure 2 Trends in place of death for patients with breast, lung, colorectal and prostate cancer and the growth of services for care towards the end of life in South East England 1985 – 2002. Note: Department of Health Data is only available for 1991 – 2001 and Hospice Information Directories are not available for 1986 and 1989.

area of residence. Concentrating on the nine of 13 cancer networks that we completely cover, the adjusted proportion of patients dying in hospital ranged from 39% in Sussex to 60% in West London. Home deaths ranged from 16% in Surrey, West Sussex and Hampshire to 27% in South Essex. Hospice death ranged from 10% in West London to 31% in Surrey, West Sussex and Hampshire. Nursing home deaths ranged from 4% in North London to 13% in Sussex. Of London networks, South East London had the lowest rate of hospital death (49%) and the highest rate of home death (23%). Patients from more deprived areas died more often in hospital and less often at home. There was no important deprivation gradient for nursing home or hospice death.

DISCUSSION

Summary of main findings

This study of 216 404 patients diagnosed and dying from four common cancers in South East England found an initial trend away from hospital death (67-44%) to home (17-30%) and hospice death (8-20%) between 1985 and 1994. After 1995 this trend partly reversed. By 2002, the proportion of hospital deaths rose to 47%, hospice deaths remained stable, home deaths dropped to 23% and nursing home deaths rose from 3 to 8%. The number and range of palliative care services increased but trends for hospice and nursing home death most clearly followed the numbers of beds available. Analysis of individual data showed that throughout the period disease-related factors had a modest influence on place of death. Patients with colorectal cancer were more likely to die at home and in hospices while patients with lung or breast cancer, no microscopic diagnosis and no radiotherapy were more likely to die in hospitals. However, between 1998 and 2002, age and place of residence were associated with most variation. Older patients were more likely to die in hospitals and nursing homes and less likely to die at home or in hospices. Patients from deprived areas were more likely to die in hospitals and less likely to die at home. There was significant variation in each place of death by cancer network of residence.

Table I Associations of individual demographic and disease-related factors with place of death for cancer patients who died 1985–2002 in South East England

	Acute hospital		tal	Home				Hospice		N			
	Number	%	% Adj	Number	%	% Adj	Number	%	% Adj	Number	%	% Adj	Total
Age group <65 65-74 75-84 85+	28 8 1 8 34 777 33 8 1 1 10 5 1 2	47 49 52 55	47 47 48 50	17 332 18 104 13 960 3717	28 26 22 19	28 26 23 22	12 032 13 045 10 566 2046	20 18 16	20 20 18 12	956 2467 4721 2375	2 3 7 12	2 4 8 12	61 670 70 665 64 92 1 19 148
Test for Trend	χ^2 (1 df)	574.1 <0.001	51.1 <0.001		1036. 6 <0.001	410.7 <0.001		753.7 <0.001	271.2 <0.001		4322.2 <0.001	3206.3 < 0.001	
Sex Male Female	60 626 47 292	51 48	51 49	29 552 23 56 l	25 24	25 23	19 793 17 896	17 18	17 19	5005 5514	4	4	118 630 97 774
Test for Heterogeneity	χ^2 (1 df)	160.5 < 0.001	46.7 <0.001		19.2 <0.001	42.8 <0.001		97.6 <0.001	92.0 <0.001		232.3 < 0.001	139.3 < 0.00	
Basis of diagnosis Clinical Microscopic	29 382 78 536	57 48	57 52	10763 42350	21 26	21 23	6697 30 992	13 19	13 16	3283 7236	6 4	6 5	51 936 164 468
Test for Heterogeneity	χ^2 (1 df)	1222.9 < 0.001	219.3 <0.001		536.2 <0.001	128.9 <0.001		959.3 <0.001	212.1 <0.001		311.8 < 0.001	55.1 < 0.001	
Site Colorectal Lung Breast Prostate	23 203 54 794 17 375 12 546	46 54 47 48	46 54 56 52	13 381 24 738 9140 5854	26 24 24 22	26 23 21 21	9873 16 166 6904 4746	19 16 18	19 16 14 18	2705 3575 2304 1935	5 4 6 7	5 4 5 6	50 937 102 07 1 37 340 26 056
Test for Heterogeneity	χ^2 (3 df)		837.7 <0.001		47.8 <0.00	320.6 <0.001		354.4 <0.001	294.2 <0.001		910.8 <0.001		
Had noninvestigati No Yes	ve surgery 78 702 29 216	51 46	51 54	36 944 16 169	24 26	24 22	25 189 12 500	16 20	16 17	7527 2992	5 5	5 5	153 570 62 834
Test for Heterogeneity	χ^2 (1 df)	402.2 <0.001	109.0 <0.001		67.6 <0.001	61.6 <0.001		376.8 <0.001	0.3 0.618		1.9 0.171	1.1 0.298	
Had radiotherapy No Yes	79 090 28 828	52 44	52 43	34962 18151	23 28	23 27	24 472 13 217	16 20	16 20	8182 2337	5 4	5 5	151 223 65 181
Test for Heterogeneity	χ^2 (1 df)	183.5 < 0.00	1240.9 <0.001		548.2 <0.001	329.8 <0.001		528.9 <0.001	425.9 <0.001		323.6 < 0.00 l	2.5 0.117	
Had chemotherap; No Yes	94814 13104	50 46	50 49	45 22 I 7892	24 28	24 25	31 764 5 925	17 21	17 18	9976 543	5 2	5 3	187 856 28 548
Test for Heterogeneity	χ^2 (1 df)	206.7 < 0.001	12.7 < 0.00		70.4 <0.00	20.9 <0.001		253.8 <0.001	10.6 0.001		568.8 < 0.001	125.6 < 0.001	
Had hormone ther No Yes	85 818 22 100	50 48	50 49	41 640 11 473	24 25	24 25	29 243 8446	17 18	17 18	7631 2888	4	4 5	170 033 46 37 I
Test for Heterogeneity	χ^2 (1 df)	15.2 < 0.00	23.8 <0.001		1.3 0.263	8.8 0.003		26.1 <0.001	9.1 0.003		236.5 < 0.001	46.6 < 0.001	
Year of death 1985 1986 1987 1988 1989 1990 1991	3278 5473 5487 5976 6485 6558 6392	67 62 57 54 53 52 50	67 64 61 59 58 57 56	847 1792 2294 2660 3212 3415 3506	17 20 24 24 26 27 28	17 19 22 22 24 25 26	388 996 1183 1592 1718 1926 2074	8 11 12 14 14 15	8 10 11 12 12 13 14	191 328 330 396 425 420 453	4 4 3 4 3 3 4	4 4 3 3 3 3 3	4866 8833 9644 10989 12215 12659 12738

Table I (Continued)

	Acute hospital			Home				Hospice		N			
	Number	%	% Adj	Number	%	% Adj	Number	%	% Adj	Number	%	% Adj	Total
1992	6274	50	55	3318	26	24	2296	18	16	440	3	3	12 660
1993	6536	45	50	4345	30	28	2834	19	17	507	3	3	14681
1994	5342	44	50	3730	30	28	2505	20	17	339	3	2	12 279
1995	6055	47	54	3170	25	22	2242	17	15	398	3	2	12827
1996	4917	46	53	2625	25	22	2135	20	17	583	5	5	10704
1997	5606	47	54	2765	23	21	2188	18	15	631	5	4	11930
1998	6463	48	55	3062	23	20	2709	20	17	927	7	6	13501
1999	6653	48	55	3247	24	21	2675	19	17	920	7	5	13798
2000	6849	49	56	3008	22	20	2685	19	17	1019	7	6	13893
2001	6812	49	55	2892	21	19	2737	20	17	1019	7	6	13919
2002	6762	47	54	3225	23	21	2806	20	17	1193	8	7	14268
Test for	χ^2 (1 df)	906.0	353.0		68.3	119.2		949.9	672.1		1087.3	648.8	
Trend	Р	< 0.001	< 0.001		< 0.00 l	< 0.001		< 0.001	< 0.001		< 0.001	< 0.001	

Adjusted model includes: age, sex, basis of diagnosis, site, treatment (surgery, radiotherapy, chemotherapy or hormone therapy), year of death and years since diagnosis.

Table 2 Associations of individual demographic, disease-related and area of residence with place of death for patients who died from Breast, lung, colorectal or prostate cancer between 1998 and 2002 in South East England

	Acute hospital				Home		1	Hospice		Nu			
	Number	%	% Adj	Number	%	% Adj	Number	%	% Adj	Number	%	% Adj	Total
Age group													
< 65 65-74	8756 10018	45 48	45 46	5085 4963	26 24	26 24	4578 4454	23 21	23 22	411 1146	2 5	2 5	19521 21058
75-84	10018	48 50	46	4963	20	2 4 21	3727	21 17	22 19	2263	5 	10	21 058
85+	3975	54	50	1206	16	18	853	11	13	1258	17	14	7423
Test for	χ^2 (I df)	219.0	55.6		421.17	213.1		553.8	268.8		2016.8	1293.1	
Trend	Р	< 0.001	< 0.001		< 0.001	< 0.001		< 0.001	< 0.001		< 0.001	< 0.00	
Sex													
Male Female	18 074 15 465	49 47	49 47	8369 7065	23 22	23 22	7068 6544	19 20	19 20	2305 2773	6 8	6 10	36 629 32 750
					16.3	10.0		5.2	5.7		119.7		
Test for Heterogeneity	χ^2 (1 df)	31.2 <0.001	24.0 < 0.00 l		< 0.001	0.002		0.023	5.7 0.017	,	< 0.001	< 0.00	
Basis of diagnosis													
Clinical	8462 25 077	56 46	56 49	2755 12 679	18 23	18 21	1977 11 635	13 21	13 18	1472 3606	10 7	10 9	15 002 54 377
Microscopic				120/9			11633			3606			343//
Test for Heterogeneity	χ^2 (I df)	495.0 < 0.00 l	192.4 < 0.001		165.9 < 0.001	56.3 < 0.001		493.1 < 0.001	159.9 < 0.001		173.2 < 0.001	6.5 0.01	
,													
Site Colorectal	7528	45	45	3799	23	23	3564	21	21	1370	8	8	16714
Lung	15 992	53	54	6833	23	22	5429	18	18	1460	5	5	30 306
Breast	5853	45	51	2821	22	19	2722	21	18	1184	9	10	13026
Prostate	4166	45	44	1981	21	20	1897	20	22	1064	11	12	9333
Test for	χ^2 (3 df)	421.7	326.2		12.1	50.3		102.9	106.7		565.1	315.6	
Heterogeneity	Ρ	< 0.001	< 0.001		0.007	< 0.001		< 0.001	< 0.001		< 0.001	< 0.00	
Had noninvestigative surgery No	24 850	50	50	10836	22	22	9110	18	18	3646	7	7	49 630
Yes	8689	44	50	4598	23	22	4502	23	20	1432	7	7	19749
Test for	χ^2 (1 df)	208.3	1.1		17.1	0.1		176.0	12.1		0.2	0.9	
Heterogeneity	х (1 d1) Р	< 0.001	0.300)	< 0.001	0.792		< 0.001	0.001		0.663		
Had radiotherapy													
No	25 03 1	51	51	10 122	21	21	8981	18	18	3937	8	8	49 142
Yes	8508	42	41	5312	26	25	4631	23	23	1141	6	8	20 237

Table 2 (Continued)

	Acute hospital				Home		Hospice			Nursing home			
	Number	%	% Adj	Number	%	% Adj	Number	%	% Adj	Number	%	% Adj	Total
Test for Heterogeneity	χ^2 (1 df)	452.2 <0.001	525.8 < 0.00 l		263.5 < 0.001	43. < 0. 00		192.3 <0.001	62.9 < 0.00			2.4 0.122	!
Had chemotherapy No Yes	27 748 579 I	49 44	49 47	11 977 3457	21 26	21 23	10 409 3203	19 24	19 20	4764 314	8 2	8 5	56216 13163
Test for Heterogeneity	χ^2 (1 df)	122.7 < 0.00	25.4 <0.001		150.9 <0.001	25.9 <0.001		227.3 <0.001	24.1 <0.001		508.2 <0.001	97.0 <0.001	
Had hormone therapy No Yes	27 739 5800	50 43	50 46	12 320 3114	22 23	22 25	10 839 2773	19 21	19 20	3655 1423	7 	7 7	55 958 13 421
Test for Heterogeneity	χ^2 (1 df)	74.6 < 0.00	28.8 < 0.00 l		8.8 0.003	21.9 <0.001		11.5 0.001	2.3 0.130)	259.4 < 0.001	8.9 0.003	}
Network of residence North East London North London South East London South West London West London TCR part of Mount Vernon South Essex Kent & Medway Surrey, West Sussex and Hampshire Sussex TCR part of Central South Coast TCR part of Mid Anglia TCR part of West Anglia Other/NK	3946 3314 3533 2899 3988 2459 2121 3663 2688 2642 327 1734 201 24	56 54 49 49 58 50 52 42 43 38 25 52 41 46	56 55 49 51 60 53 54 42 48 39 25 53 45	1353 1224 1697 1111 1391 1415 1165 2139 1232 1515 249 791 140 12	19 20 24 19 20 29 29 24 20 22 19 24 28 23	19 19 23 17 19 26 27 23 16 20 18 22 24 21	1346 1173 1549 1472 693 488 415 2186 1771 1625 367 473 48 6	19 19 22 25 10 10 10 25 28 23 28 14 10 12	19 20 22 27 10 11 11 26 31 25 32 15	347 261 328 313 417 458 338 688 349 1046 150 328 48 7	5 4 5 5 6 9 8 8 6 15 12 10 10	5 4 5 5 6 9 8 7 5 13 10 9	7080 6128 7204 5886 6829 4924 4067 8793 6262 7001 1301 3360 492 52
Test for Heterogeneity	χ² (12 df) P	36 .2 <0.00	1219.7 <0.001		399.9 < 0.001	401.8 <0.001		1613.5 <0.001	1687.6 <0.001		943.I <0.001	690.8 < 0.001	
IMD Most affluent I 2 3 4 Least affluent 5 NK	5020 5965 6754 7692 8105	42 46 48 51 53 27	42 45 47 48 49 23	2926 3106 3177 3235 2988 2	25 24 23 21 19 18	25 23 22 20 18 17	2458 2449 2620 2891 3190 4	21 19 19 19 19 21 36	2 I 2 I 2 2 2 2 2 4 2 5 7 2	896 1125 1099 1123 834	8 9 8 7 5 9	8 8 7 7 7 5	11 850 13 071 13 936 15 181 15 330 11
Test for Trend	χ^2 (1 df)	362.7 < 0.00 l	92.2 <0.001		132.4	152.0 < 0.001		0.8 0.387	58.9 <0.001		67.5 < 0.001	4.5 0.035	i

Adjusted model includes: age, sex, basis of diagnosis, site, treatment (surgery, radiotherapy, chemotherapy or hormone therapy), cancer network of residence and deprivation.

Limitations of this study

This population-based study used data collected from medical records and death certificates for routine cancer registration. Coding officers may have missed some deaths in new nursing homes and hospices when their addresses were unfamiliar in the early part of the study period. Lack of information on death certificate on deaths in hospital palliative care units and lack of data on hospital beds meant we could not explore these trends and it is possible that excluding patients for whom we had only death certificate data from the analysis introduced some bias. Important information on patient preference for place of death, functional status, presence of a carer at home, family support, and hospital and community services received in the weeks before death (Grundy et al, 2004; Gomes and Higginson, 2006) is not routinely collected and is therefore missing from the individual analyses.

Comparison to other findings

No other large UK studies have compared overall trends in place of death with the growth of services that might support patients to die in different places. However, one study of North West England between 1993 and 2000 found that proximity to a hospice or hospital increased the chances of dying there (Gatrell et al, 2003). Studies in the US have also found that the availability of beds and physicians affects death in hospital (Fisher et al, 2003a, b). National bed data available for 1987 to 1994 when hospital deaths decreased showed a decline of 19% in the numbers of acute and general hospital beds (Department of Health, 2006). It, therefore, seems likely that the initial trend for increasing home death was in part driven by the decreased availability of hospital beds and the growth of hospice and palliative home care services. However, it is more difficult to explain the reversal of the trend for home death

after 1995 using the routine service data that is available. The number of home care teams did not decline, hospital palliative care services were only just beginning to increase and hospital beds did not increase nationally until 2001. We can speculate that the decline in home death was due to other changes in care at home including the ability of families to provide care, the prior move of some older adults into nursing homes and the move to GP cooperatives for out of hours care. These factors could all have led to increased hospital admission and fewer home deaths.

Turning to predictors of individual place of death, our finding that younger patients, patients with colorectal cancer and those living in more affluent areas died more often at home is consistent with (Higginson et al 1998, 1999) analyses of a partial national registration dataset up until 1994. However, we found that patients with breast and lung cancer were more likely to die in hospital and we were further able to show that hospital death was associated with lack of microscopic diagnosis, and no radiotherapy treatment. This suggests the late admission of patients with advanced stage of disease. Conversely our finding that a microscopically confirmed diagnosis and radiotherapy treatment were associated with home and hospice death suggests that some time within 'the system' may allow for referral to supportive services (Burge et al, 2003). A recent systematic review of factors predicting home death by Gomes and Higginson (2006) found that the six strongest predictors were patients' low functional status, their preferences, home care and its intensity, living with relatives and extended family support. Our new finding that cancer network is an important cause of variation in home death is consistent with this, and probably represents a combination of difference by area in access to home care services, and the nearness of relatives and extended family. It is very unlikely to represent underlying variation in patients' preference for place of death or functional status. Finally our finding that patients from more deprived areas were equally likely to die in hospices and nursing homes as those from affluent areas, contradicts the view that the latter may access these services more often. Inequalities in hospital and home death do, however, persist.

Implications for practice and policy

Our findings reveal that despite increased investment in and provision of palliative care services, cancer patients in South East England remain twice as likely to die in hospital (47%) than at home (23%). The proportion dying at home is now lower than a decade ago, lower than elsewhere in the UK, and far lower than most patients would prefer. Recent national policy has set out the evidence that coordinated palliative care services can allow more people to die at home if they wish (NICE, 2004a, b) and advocated equity of choice in final place of care. This study covers a period before most recent initiatives (Gold Standards Framework, 2006; Marie Curie, 2006) but the variation it finds underlines the need for much more active local surveillance to drive these policies. It also suggests that opportunities exist to learn from differing strategies, organisation and practice within cancer networks. For example, London networks might ask what it is about service provision in South East London that produces rates of home death similar to those outside London. Networks outside London might ask why hospice deaths are sometimes so high and whether nursing homes are preventing hospital admission and providing better symptom control. Our data also suggest that a good place for clinicians in primary care and acute trusts to start identifying patients in the palliative stage of disease and determining their preference for avoiding or planning admission would be the clinical diagnosis of lung or breast cancer in patients living in deprived areas for whom radiotherapy treatment is not planned. The effect of any change in practice across a network can be monitored easily by the routine work of cancer registries.

Further research

We do not yet fully understand why place of death varies across the UK, how the nexus of factors around the patient operate together to influence this (Gomes and Higginson, 2006) and why home deaths have declined and remain so low in South East England. The imaginative use of available routine data as part of the development of cancer intelligence could help us see more clearly what is happening. For example, trends within individual cancer networks could reveal the influence of different historical patterns of service provision. Ecological studies could show us what happens when a new service such as a hospice opens locally. Mapping rates geographically by primary care trust could show the influence of services (beds and teams) and workforce (district nurses (Shipman et al, 2005), Marie Curie nurses and out of hours care by general practitioners). Studies of how patients move between different services and the interdependence between services are also required. Linking hospital episode statistics data with cancer registration data will, for example, allow us to explore where patients with different cancers are admitted to hospital from, how long they stay and where they are discharged to in the last months of life. The influence that admission has on rate of death in different trusts or primary care trusts explored in a similar way to US studies have done (Wennberg et al, 2004). Qualitative case studies of selected areas could then focus on explaining how different patterns of care are perpetuated, or how change has occurred. Finally in the context of an ageing population, changes in migration and kinship patterns we need to determine older people's preference for death in institutions, ensure that the information we have on what currently occurs is available and public so that where possible people may make their own choices in planning care towards the end of life (WHO, 2004b).

ACKNOWLEDGEMENTS

We thank Hospice Information for providing us with Hospice Directories, the Department of Health for confirming the nursing home data and colleagues for helpful comments on an earlier draft of this paper.

REFERENCES

Burge F, Lawson B, Johnston G (2003) Trends in the place of death of cancer patients. Can Med Assoc J 163(3): 265-270

Department of the Environment, Transport and the Regions (2000) Indices of Deprivation 2000: Regeneration Research Summary No. 31. London: Stationery Office.

Department of Health (2006) Hospital Activity Statistics. 1987-2005, www.performance.doh.gov.uk/hospitalactivity/data_requests/download/ beds_open_overnight/beds_ts.xls (Accessed 17th March 2006)

Higginson IJ, Astin P, Dolan S (1998) Where do cancer patients die? Tenyear trends in the place of death of cancer patients in England. Palliative Med 12: 353 - 363

Higginson IJ, Jarman B, Astin P, Dolan S (1999) Do social factors affect where patients die: an analysis of 10 years of cancer deaths in England. J Public Health Med 21(1): 22-28

Hospice Information Service (2006) http://www.hospiceinformation.info/ (Accessed 10th March 2006)

- House of Commons Health Committee (2004) Palliative Care. Fourth report of the session 2003 4. London: Stationary Office
- Fisher ES, Wennberg DE, Stukel DA, Gottleib D, Lucas FL, Pinder E (2003a)
 The implications of regional variations in Medicare spending: part 1,
 utilisation of services and quality of care. Ann Intern Med 138: 273 287
- Fisher ES, Wennberg DE, Stukel DA, Gottleib D, Lucas FL, Pinder E (2003b)
 The implications of regional variations in Medicare spending: part 2,
 health outcomes and satisfaction with care. *Ann Intern Med* 138:
 288-298
- Gatrell AC, Harman JC, Francis BJ, Thomas C, Morris SM, Mclllmurray M (2003) Place of death: analysis of cancer deaths in North West England. *J Public Health Med* 25(1): 53-58
- Gold Standards Framework (2006) http://www.goldstandardsframework. nhs.uk/ (Accessed 17th March 2006)
- Gomes B, Higginson IJ (2006) Factors affecting death at home in terminally ill patients with cancer: systematic review. Br Med J 332: 515-521
- Grundy E, Mayer D, Young H, Sloggett A (2004) Living arrangements and place of death of older people with cancer in England and Wales: a record linkage study. *Br J Cancer* **91:** 907–912

- Marie Curie (2006) Liverpool Care of the Dying Pathway. http://www.lcp-mariecurie.org.uk/Accessed 10th March 2006
- National Institute for Clinical Excellence (2004a) Guidance on Cancer Services Improving Supportive and Palliative Care for Adults with Cancer. The Research Evidence. London: National Health Service
- National Institute for Clinical Excellence (2004b) Guidance on Cancer Services: Improving Supportive and Palliative Care for Adults with Cancer. The Manual. London: National Health Service
- Shipman C, Addington-Hall J, Richardson A, Burt J, Ream E, Beynon T (2005) Palliative care services in England: a survey of district nurses' views. Br J Com Nurs 10(8): 381 – 386
- Wennberg JE, Fisher ES, Stukel TA, Skinner JS, Sharp SM, Bronner KK (2004) Use of hospitals, physician visits, and hospice care during the last six months of life among cohorts loyal to highly respected hospitals in the United States. *Br Med J* 328: 607–612
- WHO Regional Office for Europe (2004a) Palliative Care The Solid Facts. Copenhagen
- WHO Regional Office for Europe (2004b) Better Palliative care for older people. Copenhagen